image

Investors

Corporate Profile

Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates that can modulate proteins within the cell.

SEC Filing Details

Document Details

Filing Date
August 10, 2020
Document Date
August 10, 2020
Form Description
A statement of beneficial ownership of common stock by certain persons
Filing Group
Other
Company
Nurix Therapeutics, Inc.
Issuer
NURIX THERAPEUTICS, INC.